Cushing's syndrome
Endocrinology · 2023–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| osilodrostat Treatment of endogenous Cushing's syndrome in adult patients who are not candidates for surgery or for whom surgery was not curative. | Sep 2024 | Not recommended | 8 individuals Australian Pituitary Foundation · Endocrine Society of Australia |
| osilodrostat Treatment of adult patients with endogenous Cushing's syndrome who are not candidates for surgery or for whom surgery was not curative. | Mar 2023 | Not recommended | 2 individuals |
Who spoke
Australian Pituitary Foundation · Endocrine Society of Australia
What the PBS pays
$1M in government benefit over 2024–25, across 168 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| osilodrostat | $0.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.